Skip to main content

Table 1 Baseline characteristics of patients with mild cognitive impairment and controls with normal cognitive function in the study

From: Association of body mass index with amnestic and non-amnestic mild cognitive impairment risk in elderly

Baseline

aMCI a

(n = 240)

naMCI a

(n = 240)

Control

(n = 480)

Male (n, %)

170 (70.8)

176 (73.3)

360 (75.0)

Age (yrs, mean ± SD) a

73.4 ± 7.7

72.6 ± 9.6

73.2 ± 6.8

Han nationality (n, %)

224 (93.3)

220 (91.7)

460 (95.8)

Education

  ≤ 12 years

112 (46.7)

107 (44.6)

231 (48.1)

 >12 years

128 (53.3)

133 (55.4)

249 (51.9)

Type 2 DM (n, %) a

70 (29.2) *

66 (27.5) *

84 (17.5)

Hypertension (n, %)

170 (70.8) * #

198 (82.5) *

256 (53.3)

CHD (n, %) a

98 (40.8) * #

134 (55.8) *

146 (30.4)

MS (n, %) a

62 (25.8) *

60 (25.0) *

76 (15.8)

Sulfonylureas (n, %)

33 (13.8) *

35 (14.6) *

41 (8.5)

Metformin (n, %)

45 (18.8) *

43 (17.9) *

61 (12.7)

Insulin (n, %)

13 (5.4)

10 (4.2)

15 (3.1)

Statins (n, %)

53 (22.1) *

58 (24.2) *

70 (14.6)

APOE4 carriers (n, %) a

72 (30.0) *

61 (25.4) *

90 (18.8)

  1. a SD standard deviation, DM diabetes mellitus, CHD coronary heart disease, MS metabolism syndrome, APOE4 apolopoprotein E4, aMCI amnestic mild cognitive impairment, naMCI non-amnestic mild cognitive impairment
  2. * Compared with control, P < 0.05; # Compared with naMCI, P < 0.05